Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03222973




Registration number
NCT03222973
Ethics application status
Date submitted
17/07/2017
Date registered
19/07/2017
Date last updated
28/04/2022

Titles & IDs
Public title
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies
Secondary ID [1] 0 0
2017-001224-22
Secondary ID [2] 0 0
215MS202
Universal Trial Number (UTN)
Trial acronym
AFFINITY
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BIIB033 (opicinumab)
Treatment: Drugs - Placebo

Experimental: BIIB033 (opicinumab) 750 mg - Participants with relapsing multiple sclerosis (RMS) will receive BIIB033 750 milligram (mg) intravenously (IV) as an add-on therapy to a background disease-modifying therapy (DMT) once every 4 weeks over 72 weeks in Part 1 and once every 4 weeks over 96 weeks in Part 2.

Placebo comparator: Placebo - Participants with RMS will receive placebo IV as an add-on therapy to a background DMT once every 4 weeks over 72 weeks in Part 1 and BIIB033 once every 4 weeks over 96 weeks in Part 2. The placebo looks like BIIB033 but does not contain the active ingredient that is thought to have an effect on MS disease. The placebo used in this study is sterile normal saline (water with a small amount of sodium chloride \[salt\]).


Treatment: Drugs: BIIB033 (opicinumab)
Administered as specified in the treatment arm

Treatment: Drugs: Placebo
Administered as specified in the treatment arm
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part 1: Overall Response Score
Timepoint [1] 0 0
Part 1: Baseline to Week 72
Primary outcome [2] 0 0
Part 2: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [2] 0 0
Part 2: Baseline to Week 169
Secondary outcome [1] 0 0
Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND
Timepoint [1] 0 0
Part 1: Baseline to Week 72
Secondary outcome [2] 0 0
Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, or 3-Second Paced Auditory Serial Addition Test (PASAT-3)
Timepoint [2] 0 0
Part 1: Baseline to Week 72
Secondary outcome [3] 0 0
Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND, and Without Confirmed Worsening in Any of the 4 Assessments During the 72 Weeks of the Study
Timepoint [3] 0 0
Part 1: Baseline to Week 72
Secondary outcome [4] 0 0
Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, and Symbol Digit Modalities Test (SDMT)
Timepoint [4] 0 0
Part 1: Baseline to Week 72
Secondary outcome [5] 0 0
Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND (20% Thresholds for T25FW and 9HPT)
Timepoint [5] 0 0
Part 1: Baseline to Week 72
Secondary outcome [6] 0 0
Part 2: Overall Response Score
Timepoint [6] 0 0
Part 2: Baseline to Week 96
Secondary outcome [7] 0 0
Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND
Timepoint [7] 0 0
Part 2: Baseline to Week 108
Secondary outcome [8] 0 0
Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, or PASAT-3
Timepoint [8] 0 0
Part 2: Baseline to Week 108
Secondary outcome [9] 0 0
Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND, and Without Confirmed Worsening in Any of the 4 Assessments During the 96 Weeks of the Study
Timepoint [9] 0 0
Part 2: Baseline to Week 96
Secondary outcome [10] 0 0
Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, and SDMT
Timepoint [10] 0 0
Part 2: Baseline to Week 108
Secondary outcome [11] 0 0
Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND (20% Thresholds for T25FW and 9HPT)
Timepoint [11] 0 0
Part 2: Baseline to Week 108
Secondary outcome [12] 0 0
Part 2: Number of Participants With Potentially Clinically Significant Abnormal Laboratory Values
Timepoint [12] 0 0
Part 2: Baseline to Week 96
Secondary outcome [13] 0 0
Part 2: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Values
Timepoint [13] 0 0
Part 2: Baseline to Week 96
Secondary outcome [14] 0 0
Part 2: Percentage of Participants With Potentially Clinically Significant Abnormal Vital Signs Values
Timepoint [14] 0 0
Part 2: Baseline to Week 96
Secondary outcome [15] 0 0
Part 2: Percentage of Participants With Potentially Clinically Significant Abnormal Weight Values
Timepoint [15] 0 0
Part 2: Baseline, Week 12, 24, 36, 48, 72 and 96
Secondary outcome [16] 0 0
Part 2: Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Score at Any Post-Baseline Visit
Timepoint [16] 0 0
Part 2: Baseline to Week 96

Eligibility
Key inclusion criteria
Key Part 1

* Baseline Expanded Disability Status Scale (EDSS) of 2.0 to 6.0, have a diagnosis of relapsing-remitting multiple sclerosis (RRMS) per the 2010 McDonald's criteria or onset of secondary progressive multiple sclerosis (SPMS) per the Lublin and Reingold criteria, and should have experienced their first MS symptom(s) within the previous 20 years.
* Subjects must have experienced at least 1 of the following within 24 months prior to Day 1/Baseline: a clinical relapse (but not within 24 weeks prior to Day 1/Baseline), gadolinium-enhancing lesions on brain or spinal cord magnetic resonance imaging (MRI), or new T2 lesion(s) on brain or spinal cord MRI.
* Subjects must be on a stable dose of a protocol-specified anti-inflammatory disease-modifying therapy (DMT) (IFNß [Avonex, Plegridy, Betaferon/Betaseron, or Rebif], dimethyl fumarate (DMF) [Tecfidera], or natalizumab [Tysabri]) for at least 24 weeks prior to enrollment.
* In addition, subjects must have met protocol-defined MRI characteristics using magnetization transfer ratio (MTR) and diffusion tensor imaging (DTI) sequences at Screening/Baseline.

Key Part 2

-Subjects who complete study treatment (BIIB033 or placebo) at Part 1/Week 72 Visit.

Key
Minimum age
18 Years
Maximum age
58 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Part 1

* Primary progressive MS
* An MS relapse that has occurred within 24 weeks prior to Day 1/Baseline or the subject has not stabilized from a previous relapse at the time of Screening.
* Treatment with any chemotherapeutic agents (e.g., mitoxantrone, cyclophosphamide, cladribine), cell-depleting monoclonal antibodies (mAbs) (e.g., rituximab, ocrelizumab, alemtuzumab), total lymphoid irradiation, T-cell or T-cell receptor vaccination, or teriflunomide within 1 year prior to Day 1/Baseline.
* Treatment with other anti-inflammatory DMTs (e.g., GA, fingolimod, daclizumab) or plasmapheresis within 24 weeks prior to Day1/Baseline.
* Treatment with Botox for limb spasticity within 24 weeks before Day 1/Baseline.
* Contraindications to MRI, for example, presence of pacemakers or other implanted metal devices (excluding dental braces), an allergy to gadolinium renal impairment, or claustrophobia that cannot be medically managed.
* History of human immunodeficiency virus or other immunodeficient conditions.
* History of malignancy; however, subjects with a history of excised or treated basal cell carcinoma or fewer than 3 squamous cell carcinomas are eligible to participate in this study.

Key Part 2

* Subjects who did not complete study treatment in Part 1/Week 72 Visit
* Subjects who have a duration >12 weeks between their Part 1/Week 72 Visit and Part 2/Day 1.
* Contraindications to MRI, for example, presence of pacemakers or other implanted metal devices (excluding dental braces), an allergy to Gd, renal impairment, or claustrophobia that cannot be medically managed.
* History of human immunodeficiency virus or other immunodeficient conditions not related to DMT treatment.
* History of malignancy unless enrollment is approved by the Sponsor; subjects with a history of excised or treated basal cell carcinoma or fewer than 3 squamous cell carcinomas are eligible to participate in this study.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/11/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
12/02/2021
Sample size
Target
Accrual to date
Final
263
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Research Site - Box Hill
Recruitment hospital [2] 0 0
Research Site - Clayton
Recruitment hospital [3] 0 0
Research Site - Heidelberg
Recruitment hospital [4] 0 0
Research Site - Melbourne
Recruitment hospital [5] 0 0
Research Site - Parkville
Recruitment hospital [6] 0 0
Research Site - New Lambton Heights
Recruitment hospital [7] 0 0
Research Site - Westmead
Recruitment postcode(s) [1] 0 0
3128 - Box Hill
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment postcode(s) [4] 0 0
3004 - Melbourne
Recruitment postcode(s) [5] 0 0
3050 - Parkville
Recruitment postcode(s) [6] 0 0
NS 2305 - New Lambton Heights
Recruitment postcode(s) [7] 0 0
2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
District of Columbia
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nevada
Country [18] 0 0
United States of America
State/province [18] 0 0
New Jersey
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Oklahoma
Country [23] 0 0
United States of America
State/province [23] 0 0
Oregon
Country [24] 0 0
United States of America
State/province [24] 0 0
Pennsylvania
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Utah
Country [28] 0 0
United States of America
State/province [28] 0 0
Washington
Country [29] 0 0
Belgium
State/province [29] 0 0
Brugge
Country [30] 0 0
Belgium
State/province [30] 0 0
Bruxelles
Country [31] 0 0
Belgium
State/province [31] 0 0
Gent
Country [32] 0 0
Belgium
State/province [32] 0 0
La Louvière
Country [33] 0 0
Belgium
State/province [33] 0 0
Leuven
Country [34] 0 0
Belgium
State/province [34] 0 0
Roeselare
Country [35] 0 0
Canada
State/province [35] 0 0
Alberta
Country [36] 0 0
Canada
State/province [36] 0 0
British Columbia
Country [37] 0 0
Canada
State/province [37] 0 0
Ontario
Country [38] 0 0
Canada
State/province [38] 0 0
Quebec
Country [39] 0 0
Czechia
State/province [39] 0 0
Brno
Country [40] 0 0
Czechia
State/province [40] 0 0
Hradec Kralove
Country [41] 0 0
Czechia
State/province [41] 0 0
Jihlava
Country [42] 0 0
Czechia
State/province [42] 0 0
Pardubice
Country [43] 0 0
Czechia
State/province [43] 0 0
Praha 2
Country [44] 0 0
France
State/province [44] 0 0
Bas Rhin
Country [45] 0 0
France
State/province [45] 0 0
Gard
Country [46] 0 0
France
State/province [46] 0 0
Gironde
Country [47] 0 0
France
State/province [47] 0 0
Haute Garonne
Country [48] 0 0
France
State/province [48] 0 0
Herault
Country [49] 0 0
France
State/province [49] 0 0
Loire Atlantique
Country [50] 0 0
France
State/province [50] 0 0
Nord
Country [51] 0 0
France
State/province [51] 0 0
Puy De Dome
Country [52] 0 0
France
State/province [52] 0 0
Rhone
Country [53] 0 0
France
State/province [53] 0 0
Somme
Country [54] 0 0
France
State/province [54] 0 0
Paris
Country [55] 0 0
Germany
State/province [55] 0 0
Baden Wuerttemberg
Country [56] 0 0
Germany
State/province [56] 0 0
Bavaria
Country [57] 0 0
Germany
State/province [57] 0 0
North Rhine-Westphalia
Country [58] 0 0
Germany
State/province [58] 0 0
Rhineland-Palatinate
Country [59] 0 0
Germany
State/province [59] 0 0
Saxony
Country [60] 0 0
Germany
State/province [60] 0 0
Berlin
Country [61] 0 0
Germany
State/province [61] 0 0
Muenster
Country [62] 0 0
Hungary
State/province [62] 0 0
Budapest
Country [63] 0 0
Hungary
State/province [63] 0 0
Esztergom
Country [64] 0 0
Hungary
State/province [64] 0 0
Kistarcsa
Country [65] 0 0
Hungary
State/province [65] 0 0
Pecs
Country [66] 0 0
Israel
State/province [66] 0 0
Ramat Gan
Country [67] 0 0
Italy
State/province [67] 0 0
Brescia
Country [68] 0 0
Italy
State/province [68] 0 0
Isernia
Country [69] 0 0
Italy
State/province [69] 0 0
Palermo
Country [70] 0 0
Italy
State/province [70] 0 0
Genova
Country [71] 0 0
Italy
State/province [71] 0 0
Messina
Country [72] 0 0
Italy
State/province [72] 0 0
Milano
Country [73] 0 0
Italy
State/province [73] 0 0
Napoli
Country [74] 0 0
Italy
State/province [74] 0 0
Pisa
Country [75] 0 0
Italy
State/province [75] 0 0
Roma
Country [76] 0 0
Italy
State/province [76] 0 0
Verona
Country [77] 0 0
Netherlands
State/province [77] 0 0
Geleen
Country [78] 0 0
Poland
State/province [78] 0 0
Bydgoszcz
Country [79] 0 0
Poland
State/province [79] 0 0
Gdansk
Country [80] 0 0
Poland
State/province [80] 0 0
Katowice
Country [81] 0 0
Poland
State/province [81] 0 0
Krakow
Country [82] 0 0
Poland
State/province [82] 0 0
Lodz
Country [83] 0 0
Poland
State/province [83] 0 0
Lublin
Country [84] 0 0
Poland
State/province [84] 0 0
Szczecin
Country [85] 0 0
Poland
State/province [85] 0 0
Warszawa
Country [86] 0 0
Poland
State/province [86] 0 0
Zabrze
Country [87] 0 0
Spain
State/province [87] 0 0
Girona
Country [88] 0 0
Spain
State/province [88] 0 0
Madrid
Country [89] 0 0
Spain
State/province [89] 0 0
Vizcaya
Country [90] 0 0
Spain
State/province [90] 0 0
Barcelona
Country [91] 0 0
Spain
State/province [91] 0 0
Cordoba
Country [92] 0 0
Spain
State/province [92] 0 0
Sevilla
Country [93] 0 0
Switzerland
State/province [93] 0 0
Aarau
Country [94] 0 0
Switzerland
State/province [94] 0 0
Basel
Country [95] 0 0
Switzerland
State/province [95] 0 0
Bern
Country [96] 0 0
Switzerland
State/province [96] 0 0
Lugano
Country [97] 0 0
Switzerland
State/province [97] 0 0
Zurich
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Devon
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Greater London
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Greater Manchester
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Merseyside
Country [102] 0 0
United Kingdom
State/province [102] 0 0
Nottinghamshire
Country [103] 0 0
United Kingdom
State/province [103] 0 0
Oxfordshire
Country [104] 0 0
United Kingdom
State/province [104] 0 0
Strathclyde
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Tyne & Wear
Country [106] 0 0
United Kingdom
State/province [106] 0 0
West Yorkshire
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Brighton
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Sheffield
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Swansea

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Biogen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of Part 1 of this study is to evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks. The primary objective of Part 2 of this study is to evaluate the long-term safety profile of BIIB033 as an add-on therapy in participants with MS.

The secondary objective of Part 1 is to evaluate the effects of BIIB033 versus placebo on additional measures of disability improvement. The secondary objective of Part 2 is to investigate long-term efficacy (disability improvement) and additional safety measures of BIIB033 as an add-on therapy in participants with MS.
Trial website
https://clinicaltrials.gov/study/NCT03222973
Trial related presentations / publications
Hanf KJM, Arndt JW, Liu Y, Gong BJ, Rushe M, Sopko R, Massol R, Smith B, Gao Y, Dalkilic-Liddle I, Lee X, Mojta S, Shao Z, Mi S, Pepinsky RB. Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding site. MAbs. 2020 Jan-Dec;12(1):1713648. doi: 10.1080/19420862.2020.1713648.
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Biogen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03222973